| Medical Degree: |
M.D., University of Pennsylvania School of Medicine
|
|---|
| Mailing Address: |
8900 Wilshire Blvd.
Beverly Hills, CA 90211
UNITED STATES
|
|---|
|
Work Phone Number:
|
(310) 272-7640
|
|---|
David B. Agus received his undergraduate degree from Princeton University and his M.D. from the University of Pennsylvania School of Medicine. Dr. Agus then spent two years at the National Institutes of Health as a Howard Hughes Medical Institute-NIH Research Scholar and did his medical internship and residency training as part of the Osler housestaff at the Johns Hopkins Hospital. Dr. Agus completed his oncology fellowship training at Memorial Sloan-Kettering Cancer Center in New York City where later he served as an attending physician in the Department of Medical Oncology and as head of the Laboratory of Tumor Biology. He also held a position as Assistant Professor of Medicine at Cornell University Medical Center. Dr. Agus received various honors and awards, including the American Cancer Society Physician Research Award, a Clinical Scholar Award from the Sloan-Kettering Institute, a CaP CURE Young Investigator Award and the American Cancer Society Clinical Oncology Fellowship Award. Dr. Agus currently serves as Research Director of the Prostate Cancer Center at Cedars-Sinai Medical Center and Director of the Spielberg Family Center for Applied Proteomics and Associate Professor at the UCLA School of Medicine. Dr. Agus' research is focused on the application of proteomics and genomics for the study of cancer and the development of new therapeutics for cancer. Dr. Agus has clinical responsibilities that include the development of clinical trials of new drugs for the treatment of cancer. He currently sees patients at Cedars-Sinai Medical Center in Los Angeles, California.
|
|
|
Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer..
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. .
2005; 23(11):
2534-43.
Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma..
Cancer cell. .
2004; 5(6):
565-74.
Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group..
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. .
2004; 22(3):
537-56.
Gross ME, Shazer RL, Agus DB Targeting the HER-kinase axis in cancer..
Seminars in oncology. .
2004; 31(1 Suppl 3):
9-20.
Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse..
Cancer research. .
2003; 63(14):
4196-203.
Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth..
Cancer cell. .
2002; 2(2):
127-37.
|
|
Disability Resources
